JP2017510262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510262A5 JP2017510262A5 JP2016555659A JP2016555659A JP2017510262A5 JP 2017510262 A5 JP2017510262 A5 JP 2017510262A5 JP 2016555659 A JP2016555659 A JP 2016555659A JP 2016555659 A JP2016555659 A JP 2016555659A JP 2017510262 A5 JP2017510262 A5 JP 2017510262A5
- Authority
- JP
- Japan
- Prior art keywords
- hsv
- recombinant
- glycoprotein
- herpes simplex
- simplex virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946965P | 2014-03-03 | 2014-03-03 | |
| US61/946,965 | 2014-03-03 | ||
| US201462080663P | 2014-11-17 | 2014-11-17 | |
| US62/080,663 | 2014-11-17 | ||
| PCT/US2015/018272 WO2015134368A2 (en) | 2014-03-03 | 2015-03-02 | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020009043A Division JP6844045B2 (ja) | 2014-03-03 | 2020-01-23 | 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510262A JP2017510262A (ja) | 2017-04-13 |
| JP2017510262A5 true JP2017510262A5 (enExample) | 2018-04-12 |
| JP6652497B2 JP6652497B2 (ja) | 2020-02-26 |
Family
ID=54055977
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555659A Active JP6652497B2 (ja) | 2014-03-03 | 2015-03-02 | 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター |
| JP2020009043A Active JP6844045B2 (ja) | 2014-03-03 | 2020-01-23 | 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター |
| JP2021026943A Active JP7050193B2 (ja) | 2014-03-03 | 2021-02-24 | 組換え単純ヘルペスウィルス２（ｈｓｖ－２）ワクチンベクター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020009043A Active JP6844045B2 (ja) | 2014-03-03 | 2020-01-23 | 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター |
| JP2021026943A Active JP7050193B2 (ja) | 2014-03-03 | 2021-02-24 | 組換え単純ヘルペスウィルス２（ｈｓｖ－２）ワクチンベクター |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US9999665B2 (enExample) |
| EP (2) | EP3943106A1 (enExample) |
| JP (3) | JP6652497B2 (enExample) |
| CN (2) | CN110938604B (enExample) |
| AU (2) | AU2015225499B2 (enExample) |
| WO (1) | WO2015134368A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10918712B2 (en) * | 2014-03-03 | 2021-02-16 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors |
| WO2015134368A2 (en) * | 2014-03-03 | 2015-09-11 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
| AU2019260757B2 (en) | 2018-04-27 | 2023-09-28 | Krystal Biotech, Inc. | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
| JP7671982B2 (ja) * | 2018-05-01 | 2025-05-07 | アルベルト・アインシュタイン・カレッジ・オブ・メディシン | ＨＳＶ－２－ＤＥＬＴＡ－ｇＤ ワクチンおよびそれらの生産および使用のための方法 |
| WO2020056411A1 (en) * | 2018-09-14 | 2020-03-19 | Excell Biotech, Llc | Recombinant herpes simplex virus 1 (hsv-1) |
| AU2019362902A1 (en) * | 2018-10-17 | 2021-04-29 | Albert Einstein College Of Medicine | Method of enhancing antibody-dependent cell-mediated cytotoxicity (adcc) |
| CA3124523A1 (en) * | 2019-01-03 | 2020-07-09 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
| CA3179416A1 (en) * | 2020-04-07 | 2021-10-14 | Albert Einstein College Of Medicine | Method of treating and preventing ocular disease with hsv-2 delta gd |
| CA3184459A1 (en) | 2020-05-29 | 2021-12-02 | Albert Einstein College Of Medicine | Methods of using hsv-2 single cycle virus delta-gd and hsv-2 recombinant glycoprotein d |
| JP2023542535A (ja) | 2020-09-24 | 2023-10-10 | アルベルト・アインシュタイン・カレッジ・オブ・メディシン | Ａｔｔｂ細胞系、それに由来するトランスジェニック細胞系、およびそれらを製造する方法 |
| WO2023245159A1 (en) * | 2022-06-16 | 2023-12-21 | Albert Einstein College Of Medicine | Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines |
| CN119730878A (zh) * | 2022-08-05 | 2025-03-28 | 苏州亦诺微医药科技有限公司 | 复制缺陷型单纯疱疹病毒1型病毒疫苗 |
| WO2024081865A2 (en) * | 2022-10-14 | 2024-04-18 | Arizona Board Of Regents On Behalf Of Arizona State University | Recombinant immune complexes targeting herpes simplex virus |
| WO2025231288A2 (en) | 2024-05-01 | 2025-11-06 | Viradigm, Inc. | Hsv vectors having improved safety profiles |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT77014B (en) * | 1982-07-20 | 1986-01-24 | Molecular Genetics Inc | Production of herpes simplex viral proteins |
| NZ209308A (en) * | 1983-08-30 | 1991-08-27 | Genentech Inc | Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein |
| EP0231209B1 (en) * | 1985-07-29 | 1991-02-06 | The Upjohn Company | Virus vaccine |
| US5646041A (en) * | 1987-02-12 | 1997-07-08 | Harfeldt; Elisabeth | Monoclonal antibody to herpes simplex virus and cell line producing same |
| CA2158148A1 (en) * | 1993-03-19 | 1994-09-29 | Stephen Charles Inglis | Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
| US20030083289A1 (en) * | 1995-10-19 | 2003-05-01 | Boursnell Michael Edward Griffith | Herpesvirus vectors and their uses |
| CN1120238C (zh) * | 1998-05-04 | 2003-09-03 | 本元正阳基因技术股份有限公司 | 以粘粒为基础构建重组单纯疱疹病毒及其用途 |
| DK1238086T3 (da) * | 1999-12-17 | 2006-06-26 | Wyeth Corp | Vaccine til forögelse af immunreaktioner på herpes simplex virus |
| WO2005005637A2 (en) * | 2003-05-09 | 2005-01-20 | Medigene, Inc. | Herpes simplex virus comprising a genetically modified glycoprotein d |
| US6984492B2 (en) * | 2003-09-05 | 2006-01-10 | Talecris Biotherapeutics, Inc. | Methods and compositions for treating herpes infections |
| US20080089910A1 (en) | 2004-06-29 | 2008-04-17 | Visalli Et Al | Attenuated Herpes Simplex Virus Type-2, Vectors Thereof and Immunogenic Compositions Thereof |
| JP2008507784A (ja) | 2004-07-26 | 2008-03-13 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 実行可能医療ガイドラインの実行をシミュレートするための意思決定支援システム |
| CA2663109A1 (en) * | 2006-09-08 | 2008-03-13 | The Trustees Of The University Of Pennsylvania | Hsv-1 and hsv-2 vaccines and methods of use thereof |
| US8865185B2 (en) * | 2006-09-08 | 2014-10-21 | The Trustees Of The University Of Pennsylvania | Methods of use for HSV-1 and HSV-2 vaccines |
| US9284355B2 (en) * | 2006-12-28 | 2016-03-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
| US8999668B2 (en) * | 2008-01-03 | 2015-04-07 | Cornell Research Foundation, Inc. | Glycosylated protein expression in prokaryotes |
| CN101288770A (zh) * | 2008-03-14 | 2008-10-22 | 浙江省医学科学院 | 新型单纯疱疹病毒ⅱ型dna疫苗 |
| AU2010249330B2 (en) * | 2009-05-22 | 2015-11-05 | Genocea Biosciences Inc. | Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response |
| US20120219579A1 (en) * | 2009-09-18 | 2012-08-30 | Fraunhofer Usa Inc. | Virus like particles comprising target proteins fused to plant viral coat proteins |
| US10918712B2 (en) | 2014-03-03 | 2021-02-16 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors |
| WO2015134368A2 (en) | 2014-03-03 | 2015-09-11 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
-
2015
- 2015-03-02 WO PCT/US2015/018272 patent/WO2015134368A2/en not_active Ceased
- 2015-03-02 EP EP20195405.4A patent/EP3943106A1/en active Pending
- 2015-03-02 EP EP15758673.6A patent/EP3113801B1/en active Active
- 2015-03-02 CN CN201911344961.3A patent/CN110938604B/zh active Active
- 2015-03-02 CN CN201580022222.6A patent/CN106456805B/zh active Active
- 2015-03-02 AU AU2015225499A patent/AU2015225499B2/en active Active
- 2015-03-02 JP JP2016555659A patent/JP6652497B2/ja active Active
-
2016
- 2016-02-04 US US15/015,322 patent/US9999665B2/en active Active
-
2017
- 2017-03-10 US US15/455,495 patent/US10076568B2/en active Active
-
2018
- 2018-06-01 US US15/995,471 patent/US10391165B2/en active Active
-
2019
- 2019-07-30 US US16/526,056 patent/US10751411B2/en active Active
-
2020
- 2020-01-23 JP JP2020009043A patent/JP6844045B2/ja active Active
- 2020-08-10 AU AU2020217310A patent/AU2020217310B2/en active Active
- 2020-08-18 US US16/995,926 patent/US10980874B2/en active Active
-
2021
- 2021-02-24 JP JP2021026943A patent/JP7050193B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510262A5 (enExample) | ||
| JP7050193B2 (ja) | 組換え単純ヘルペスウィルス２（ｈｓｖ－２）ワクチンベクター | |
| Sun et al. | Protection against lethal challenge by Ebola virus-like particles produced in insect cells | |
| Wu et al. | A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis | |
| RU2012146775A (ru) | Вирусная частица, высвобождающаяся после инфицирования клеток млекопитающих цитомегаловирусом человека (hcmv), содержащая слитый белок, и ее применение | |
| Joshi et al. | Protective efficacy of an orf virus-vector encoding the hemagglutinin and the nucleoprotein of influenza A virus in swine | |
| de Swart et al. | Advantages and challenges of Newcastle disease virus as a vector for respiratory mucosal vaccines | |
| Wang et al. | Recombinant rabies virus expressing IFNα1 enhanced immune responses resulting in its attenuation and stronger immunogenicity | |
| Macdonald et al. | Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease | |
| Jindra et al. | Attenuated recombinant influenza A virus expressing HPV16 E6 and E7 as a novel therapeutic vaccine approach | |
| Chi et al. | Inactivated rabies virus vectored MERS-coronavirus vaccine induces protective immunity in mice, camels, and alpacas | |
| US10918712B2 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors | |
| CN112955176A (zh) | H3流感病毒的广泛反应免疫原、组合物及其使用方法 | |
| Reguzova et al. | A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge | |
| CA3124523A1 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| Liu et al. | Construction of an expression system for bioactive IL-18 and generation of recombinant canine distemper virus expressing IL-18 | |
| US20220088185A1 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| CA2942166C (en) | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| Morozova | The problems and perspectives of prevention, diagnostic and treatment of tick-borne encephalitis | |
| Konrath | Modifying Antibody Responses to Respiratory Viruses Using Structure-Guided Nanoparticle Vaccine Design | |
| Adeyemi | A bacteriophage-based, highly efficacious, needle and adjuvant-free, mucosal COVID-19 vaccine | |
| Falkeborn | Nasal Vaccination Using Novel Mucosal Adjuvants–With Main Focus on Influenza A Virus | |
| Song et al. | Induction of antibody and interferon-γ production in mice immunized with virus-like particles of swine hepatitis E virus | |
| Tully | Towards the development of a universal influenza vaccine: investigating viral-vectored vaccine-induced heterosubtypic immune responses to influenza A | |
| HK40022690B (zh) | 重组单纯疱疹病毒2(hsv-2)疫苗载体 |